RP-5063

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
RP-5063
Accession Number
DB09226
Type
Small Molecule
Groups
Investigational
Description

RP5063, also known as RP5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.

Structure
Thumb
Synonyms
  • 6-(4-(4-(2,3-Dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one
External IDs
RP-5000 / RP-5063 / RP5000 / RP5063
Product Ingredients
IngredientUNIICASInChI Key
RP-5063 hydrochlorideI440YY0HX01708960-04-6GMTQOJSRMVAFIF-UHFFFAOYSA-N
Categories
UNII
X8L60BA01I
CAS number
1239729-06-6
Weight
Average: 450.36
Monoisotopic: 449.1272971
Chemical Formula
C22H25Cl2N3O3
InChI Key
PMKMNTBZJOXTJW-UHFFFAOYSA-N
InChI
InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)
IUPAC Name
6-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2H-1,4-benzoxazin-3-ol
SMILES
OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2

Pharmacology

Indication

Investigated for the treatment of schizophrenia and schizoaffective disorder.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineRP-5063 may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when RP-5063 is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineRP-5063 may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,5-DinitrocatecholThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with RP-5063.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with RP-5063.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with RP-5063.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when RP-5063 is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with RP-5063.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with RP-5063.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with RP-5063.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910419
ChemSpider
64853808
Wikipedia
RP5063

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Schizophrenia / Schizoaffective Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0132 mg/mLALOGPS
logP4.58ALOGPS
logP2.14ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)3.14ChemAxon
pKa (Strongest Basic)7.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity121.73 m3·mol-1ChemAxon
Polarizability47.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 22, 2015 14:46 / Updated on November 02, 2018 09:16